Adaptimmune Therapeutics plc Stock Price and Value Analysis

Should you buy Adaptimmune Therapeutics plc stock? (NasdaqGS:ADAP). Let's see how it does in our automated value investing analysis system.

ADAP Free Cash Flow Trend

Free Cash Flow trendline for ADAP
Free Cash Flow trendline for Adaptimmune Therapeutics plc

Hmm, we can't give any reliable projection for Adaptimmune Therapeutics plc's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company has amazingly consistent growth!
  • This company is not making money.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company pays no dividend.

Inside the ADAP Numbers

ADAP Price
(Adaptimmune Therapeutics plc stock price per share)
PE Ratio versus Sector 100% lower than other Healthcare stocks
PE Ratio versus Industry 100% lower than other Biotechnology stocks

Is Adaptimmune Therapeutics plc Stock on Sale?

Based on our analysis, we believe that you should not buy Adaptimmune Therapeutics plc right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ADAP Stock?

Does Adaptimmune Therapeutics plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.